Recent research into scleroderma highlights key findings. A study explores the role of functional antibodies in gastrointestinal and extraintestinal features of systemic sclerosis, suggesting their potential impact on disease severity. Additionally, type 1 interferons have been identified as potential biomarkers for predicting outcomes in patients with diffuse cutaneous systemic sclerosis.
These findings emphasize the need for early detection and aggressive treatment to prevent severe outcomes. Ongoing research and funding initiatives are driving innovation in scleroderma treatment and understanding. The identification of biomarkers like type 1 interferons is crucial for managing scleroderma, as noted in recent studies (Ayla, 2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar